Nexviadyme الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

nexviadyme

sanofi b.v. - avalglucosidase alfa - glycogen opbevaring sygdom type ii - andre alimentary tract and metabolism produkter, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).